Published in Cancer Med on February 24, 2013
Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
Neoadjuvant Ipilimumab in Prostate Cancer | NCT01194271
Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer | NCT01377389
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | NCT00064129
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00323882
MDX-010 for Advanced Prostate Cancer | NCT00170157
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | NCT01530984
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol (2010) 2.51
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol (2010) 2.28
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res (2007) 1.94
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci (2007) 1.89
Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48
Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol (2005) 1.29
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19
Prostate cancer immunotherapy. Clin Cancer Res (2011) 1.11
Cancer and immune response: old and new evidence for future challenges. Oncologist (2008) 1.05
Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med (2012) 1.04
Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res (2011) 1.02
Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression. Lab Invest (2008) 1.01
Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol (2011) 0.91
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol (2008) 4.23
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med (2013) 4.23
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol (2009) 2.56
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31
Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol (2013) 2.28
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol (2002) 2.25
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res (2007) 2.03
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 1.95
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol (2004) 1.86
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol (2005) 1.72
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol (2009) 1.67
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol (2012) 1.65
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant (2006) 1.63
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res (2005) 1.61
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 1.48
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol (2005) 1.39
Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol (2002) 1.39
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs (2007) 1.37
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int (2006) 1.34
Bladder cancer. J Natl Compr Canc Netw (2009) 1.32
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst (2013) 1.27
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer (2010) 1.23
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol (2003) 1.17
Update on chemotherapy for advanced bladder cancer. J Urol (2005) 1.15
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol (2002) 1.14
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol (2012) 1.09
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer (2011) 1.08
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol (2007) 1.07
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer (2006) 1.05
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer (2006) 1.04
Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw (2006) 1.04
Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol (2006) 1.04
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology (2005) 1.03
Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. Cancer (2006) 1.03
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer (2006) 1.03
Hormone-refractory Prostate Cancer. Curr Treat Options Oncol (2002) 1.02
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res (2009) 1.01
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst (2013) 1.00
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer (2011) 1.00
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol (2013) 0.99
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int (2007) 0.99
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw (2014) 0.99
Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology (2003) 0.98
Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer (2007) 0.98
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res (2004) 0.98
Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol (2007) 0.97
Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 0.97
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer (2007) 0.96
Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol (2010) 0.96
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol (2003) 0.95
The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. J Urol (2007) 0.95
Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol (2008) 0.94
Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther (2006) 0.94
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer (2005) 0.92
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int (2006) 0.92
Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res (2005) 0.92
Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer (2002) 0.92
Bladder cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2005) 0.91
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer (2005) 0.90
Practice and progress in kidney cancer: methodology for novel drug development. J Urol (2004) 0.89
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer (2008) 0.88